Read by QxMD icon Read

infusion chemotherapy

Guoliang Qiao, Xiao-Li Wang, Lei Zhou, Xin-Na Zhou, Yuguang Song, Shuo Wang, Lei Zhao, Michael A Morse, Amy Hobeika, Jin Song, Xin Yi, Xuefeng Xia, Jun Ren, Herbert Kim Lyerly
PURPOSE: We have assessed the combination of DC-CIK with S-1 plus cisplatin chemotherapy in advanced gastric cancer(AGC) and the role of mutational analysis of circulating tumor DNA(ctDNA) and T cell receptor (TCR) repertoire in predicting clinical outcomes. EXPERIMENTAL DESIGN: Consecutive patients (n=63) with advanced gastric cancer were allocated to treatment with S-1 alone, S-1 plus cisplatin, DC-CIK combined with S-1 or DC-CIK combined with S-1 plus cisplatin...
December 4, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Ying Zhan, Lihua Wang, Guangyang Liu, Xiaohui Zhang, Jingci Yang, Yuxia Pan, Jianmin Luo
Hematological patients who accept chemotherapy always develop secondary tumor or even die of severe infections. As an important central lymphoid organ, the thymus is frequently damaged during chemotherapy. Previous studies showed that the mesenchymal stem cells (MSCs) can promote the proliferation and repair of epithelial cells in thymus. The purpose of our study is to investigate the reparative effects of human adipose-derived mesenchymal stem cells (hADMSCs) for chemotherapy treated damaged thymus. 80 mice were randomly divided into four groups: normal group, model control group, hADMSCs untreated group and hADMSCs treated group...
December 4, 2018: Stem Cells and Development
Paolo Cotogni, Cristina Barbero, Mauro Rinaldi
AIM: To investigate the incidence and risk factors for vancomycin concentrations less than 10 mg/L during cardiac surgery. METHODS: In this prospective study, patients undergoing cardiac surgery received a single dose of 1000 mg of vancomycin. Multiple arterial samples were drawn during surgery. Exclusion criteria were hepatic dysfunction; renal dysfunction; ongoing infectious diseases; solid or hematologic tumors; severe insulin-dependent diabetes; body mass index of < 17 or > 40 kg/m2 ; pregnancy or lactation; antibiotic, corticosteroid, or other immunosuppressive therapy; vancomycin or nonsteroidal anti-inflammatory drug therapy in the previous 2 wk; chemotherapy or radiation therapy in the previous 6 mo; allergy to vancomycin or cefazolin; drug abuse; cardiac surgery in the previous 6 mo; previous or scheduled organ transplantation; preoperative stay in the intensive care unit for more than 24 h; emergency procedure or lack of adequate preparation for surgery; and participation in another trial...
November 26, 2018: World Journal of Cardiology
Salvatore Amodeo, Antonio Masi, Marcovalerio Melis, Theresa Ryan, Howard S Hochster, Deirdre J Cohen, Anurag Chandra, H Leon Pachter, Elliot Newman
Background: Half of patients with pancreatic adenocarcinoma (PC) present with regionally advanced disease. This includes borderline resectable and locally advanced unresectable tumors as defined by current NCCN guidelines for resectability. Chemoradiation (CH-RT) is used in this setting in attempt to control local disease, and possibly downstage to resectable disease. We report a phase I/II trial of a combination of 5FU/Oxaliplatin with concurrent radiation in patients presenting with borderline resectable and locally advanced unresectable pancreatic cancer...
October 2018: Journal of Gastrointestinal Oncology
Carolin C Hack, Sophia Antoniadis, Matthias W Beckmann, Anna Lisa Brandl, Peter A Fasching, Janina Hackl, Hanna Langemann, Stock Katja, Natalie Weber, Anna-Katharin Theuser
Background During cancer therapy, many patients suffer from malnutrition or vitamin deficiency. Treatment for nutrition-related deficiencies should therefore include nutritional therapy and possibly oral or intravenous substitution of micronutrients. Little information exists on multinutrient infusion therapies. The aim of this study was to develop standardized infusion protocols for integrative medicine infusions with micronutrients (IMed infusions) and to report on side effects of the treatment and patients' satisfaction with it...
November 2018: Geburtshilfe und Frauenheilkunde
Hang-Yu Zhang, Jian-Hai Guo, Song Gao, Hui Chen, Xiao-Dong Wang, Peng-Jun Zhang, Peng Liu, Guang Cao, Hai-Feng Xu, Lin-Zhong Zhu, Ren-Jie Yang, Jian Li, Xu Zhu
AIM: To analyze the survival data between patients diagnosed with right-sided primary (RSP) tumors and patients diagnosed with left-sided primary (LSP) tumors after hepatic arterial infusion chemotherapy (HAIC) at our center. METHODS: A retrospective analysis of pretreated metastatic colorectal cancer patients who received HAIC from May 2006 to August 2015 was conducted. A Cox proportional hazard regression analysis was used to assess the long-term survival outcomes...
November 15, 2018: World Journal of Gastrointestinal Oncology
Wen-Jing Yu, Xiao-Dong Mo, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Chen-Hua Yan, Huan Chen, Yu-Hong Chen, Wei Han, Feng-Rong Wang, Jing-Zhi Wang, Kai-Yan Liu, Xiao-Jun Huang
The aim of this study was to investigate the occurrence and severity of chemotherapy plus donor lymphocyte infusion (Chemo-DLI) associated chronic graft-versus-host disease (cGVHD) in a consecutive cohort of patients with acute leukemia who experienced relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT; n = 104). The 5-year cumulative incidence of complete remission (CR) after Chemo-DLI was 81.0% (95% CI, 73.3-88.7%) and 84.6% (95% CI, 74.5-94.7%) in the moderate and severe cGVHD groups, respectively, which was significantly higher than that of the mild cGVHD 40...
November 25, 2018: Biology of Blood and Marrow Transplantation
Zehua Wu, Yanhong Deng
Nowadays, systemic chemotherapy with intravenous (IV) 5-fluorouracil (5-FU) remains the most commonly prescribed treatment for metastatic colorectal cancers (CRC), in combination with other cytotoxic drugs. 5-FU can be administered through a bolus injection or continuous infusion (cIV), with the latter becoming the preferred administration method and standard of care in recent years. Oral fluoropyrimidines were developed to overcome challenges associated with the IV administration of 5-FU, among which capecitabine has become the most widely used one...
November 27, 2018: Current Treatment Options in Oncology
Daniel Y Lee, Kwang Suk Lim, Gabriel M Valencia, Minjin Jung, David A Bull, Young-Wook Won
Conventional combinatorial anticancer therapy has shown promising outcomes; still, a significant interest in developing new methods to reinforce and possibly merge chemotherapy and immunotherapy persists. Here, a new one-step method that immediately modifies immune cells into a targeted form of chemoimmunotherapy through spontaneous and rapid incorporation of hydrophobized antibody-drug conjugates (ADCs) on the surface of immune cells is presented. Therapeutic objectives of this approach include targeted delivery of a potent chemotherapeutic agent to avoid adverse effects, enhancing the mobilization of infused immune cells toward tumor sites, and preserving the intense cytotoxic activities of immune cells against tumor cells...
November 2018: Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
Jia-Yan Ni, Shan-Shan Liu, Hong-Liang Sun, Wei-Dong Wang, Ze-Long Zhong, Si-Nan Hou, Yao-Ting Chen, Lin-Feng Xu
Objective: To compare the clinical efficacy and safety of transcatheter hepatic arterial infusion chemotherapy (HAIC) with those of sorafenib in the treatment of patients with hepatocellular carcinoma (HCC) of Barcelona Clinic Liver Cancer (BCLC) stage C. Methods: Potentially relevant studies comparing the clinical efficacy and safety of HAIC with those of sorafenib were searched using Medline, PubMed, Embase, Cochrane Library, and Chinese databases (Wanfang Data and China National Knowledge Infrastructure)...
2018: OncoTargets and Therapy
XiaoFang Xiao, XingNong Ye, Cheng Xu, Jian Huang
Objective: Acute lymphoblastic leukemia (ALL) is a malignant disease characterized by the accumulation of lymphoblasts, and a poor prognosis for adults with ALL is closely associated with disease recurrence. Thus far, treatment approaches have been limited, particularly in patients who are unable to tolerate chemotherapy. In this study, we report an effective treatment for such patients. Materials and methods: A 52-year-old man diagnosed with Ph-negative B-precursor ALL went into remission after inductive treatment...
2018: OncoTargets and Therapy
Marie Tauber, Romain Cohen, Pauline Laly, Laurence Josselin, Thierry André, Arsène Mekinian
Immune-related adverse events (irAEs), have been reported under immune checkpoint inhibitors. Nivolumab plus ipilimumab (N + I) demonstrated meaningful improvements in key patient-reported outcomes, in patients with pretreated microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC). We report a case of severe necrotizing myositis which occurred in a patient treated with N + I combination for mCRC MSI-H. A 61-year-old woman was diagnosed with mCRC MSI-H and BRAFV600E mutated with synchronous liver, pleural, and lymph nodes metastases...
November 19, 2018: Clinical Rheumatology
Shinichi Ikuta, Tsukasa Aihara, Naoki Yamanaka
Aim of the study: To evaluate the efficacy of sequential combination therapy using sorafenib and hepatic arterial infusion chemotherapy (HAIC) in patients with Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma (HCC). Material and methods: We recruited 98 BCLC stage B/C HCC patients at our institute, who received either sorafenib monotherapy or planned sequential sorafenib-HAIC combination therapy. A total of 26 patients (combination group) received sorafenib for one or two months, followed by HAIC with a single dose of cisplatin-lipiodol suspension and a continuous infusion of 5-fluorouracil...
2018: Contemporary Oncology Współczesna Onkologia
Pauline E McEwan, Lynn Bailey, David Trost, Christopher Scull, John H Keating, Misty Williams, Robert J Guttendorf
Regional therapies for metastatic liver disease have garnered interest in recent years due to technological advances in drug delivery. A percutaneous hepatic perfusion (PHP) using a newly developed generation 2 (GEN2) filtration system was designed to mitigate systemic toxicity and cardiovascular risk associated with hepatic blood filtration during hepatic artery infusion of the chemotherapy drug melphalan. The GEN2 system was evaluated in healthy swine, and plasma samples were assessed for clinical chemistry, melphalan toxicokinetics (TK), inflammatory cytokines, catecholamines, hematological, and cardiac biomarkers...
November 19, 2018: International Journal of Toxicology
Yunami Yamada, Hironori Fujii, Daichi Watanabe, Hiroko Kato-Hayashi, Koichi Ohata, Ryo Kobayashi, Takuma Ishihara, Shinya Uemura, Takuji Iwashita, Masahito Shimizu, Akio Suzuki
While modified FOLFIRINOX therapy is effective for treating advanced pancreatic cancer, it frequently causes severe neutropenia. The present study investigated the effect of severe neutropenia on clinical outcomes in advanced pancreatic cancer patients who received modified FOLFIRINOX. The study subjects were 51 patients (30 males and 21 females) with advanced pancreatic cancer who received modified FOLFIRINOX (2h bolus injection of oxaliplatin at 85 mg/m², 2 h bolus injection of L-leucovorin at 200 mg/m², 90min bolus injection of irinotecan at 150 mg/m², followed by continuous infusion of 5-fluorouracil for 46 h at 2400 mg/m² without bolus 5-fluorouracil) during the period from January 2014 to May 2018...
November 16, 2018: Cancers
Jaya Mini Gill, Janice Frost, Rachelle Park, Marlon G Saria
Venous flare reaction, a localized allergic response associated with the administration of an irritant, is one of the most common chemotherapy infusion-related reactions. Etoposide, a drug commonly used in patients with lung cancer, has been reported to be an irritant with vesicant properties depending on the volume administered. This article presents the case of a patient who has a venous flare reaction immediately following the administration of etoposide for the treatment of diffuse large B-cell lymphoma...
December 1, 2018: Clinical Journal of Oncology Nursing
Clara Beaver
Vincristine is a cytotoxic chemotherapy agent classified as an antitumor alkaloid and is part of the vinca alkaloid family. Vincristine's mechanism of action is to primarily inhibit mitosis of the cancer cell and is given by IV route only for treatment. Accidental intrathecal administration of vincristine has lethal consequences for patients. To minimize the risk of accidental intrathecal administration of vincristine, 14 infusion centers participated in a quality improvement project to change the practice of vincristine administration from IV push to IV piggyback via minibag and gravity...
December 1, 2018: Clinical Journal of Oncology Nursing
A Partanen, J Valtola, A Ropponen, H Kuitunen, O Kuittinen, K Vasala, L Ågren, K Penttilä, L Keskinen, M Pyörälä, T Nousiainen, T Selander, P Mäntymaa, J Pelkonen, V Varmavuo, E Jantunen
BACKGROUND: Data are limited on the long-acting granulocyte-colony stimulating factors (G-CSFs) pegfilgrastim (PEG) and lipegfilgrastim (LIPEG) compared with filgrastim (FIL) regarding the mobilization efficiency of CD34+ cells, graft cellular composition, and engraftment. STUDY DESIGN AND METHODS: In this prospective nonrandomized study, 36 patients with non-Hodgkin lymphoma received FIL, 67 received PEG, and 16 patients received LIPEG as a cytokine after chemotherapy...
November 19, 2018: Transfusion
Tomohiro Tsujita, Syogo Takahashi, Toshimichi Oinuma, Norihiko Hata
The patient was a 66-year-old male. Following surgery for pulmonary adenocarcinoma in the upper right lobe and adjuvant chemotherapy, the patient relapsed. We carried out treatment using the immune checkpoint inhibitor pembrolizumab (KEYTRUDA®)for high expression of PD-L1. Following the first administration, severe drug eruption occurred and despite temporary improvement seen by intravenous infusion of steroids in combination with oral administration and external use thereof, it relapsed in the early stages and toxic epidermal necrosis developed...
November 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Hiromi Sekine, Ayumi Akaiwa, Yumiko Onozawa, Taeko Kinjo, Hitomi Nakamura, Rie Nakamura, Mieko Nawa, Shizuka Yoshida, Nobuo Araki, Makoto Iizuka, Hiroaki Shimizu, Noriaki Sunaga, Norifumi Tsukamoto
Hypersensitivity reactions(HSRs)are adverse events that are potentially caused by all anticancer agents. HSRs are unpredictable and can occur at any time, and prompt intervention is needed when symptoms occur. The types of symptoms and their degrees vary with the anticancer agent used and the number of chemotherapy cycles. Here, we evaluated the degree of HSRs and their frequencies in the outpatient chemotherapy center of Gunma University Hospital. Among 55,046 patients, 141 (0.26%)cases of HSRs and 70(0.13%)cases of infusion reactions were identified...
November 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"